Early data from US biotech Moderna has revealed that its Covid-19 vaccine candidate is 94.5 per cent effective, raising hopes that a range of immunisations will be available to help end the pandemic.
The interim analysis of the vaccine, currently known as mRNA-1273, comes after 95 trial particip...ants contracted Covid-19, including just five who were given the coronavirus jab.
more
Exciting news this week with @Pfizer reporting their mRNA vaccine is 90% effective, based on their Phase III clinical trial data. Dr. Tom looks inside the virus to break down how mRNA vaccines work, and whether news this promising means we can finally relax.
Warum die Covid-19 RNA Impfung dein Erbgut nicht verändert und wie genau sie funktioniert. Frisch erklärt von deinem Impf-fluencer.
Produziert im Rahmen der #EUMythBusters.
This article is part four in a series of explainers on vaccine development and distribution.
Part one focused on how vaccines work to protect our bodies from disease-carrying germs.
Part two focused on the ingredients in a vaccine and the three clinical trial phases.
Part three focused on the ste...ps from completing the clinical trial phases through to distribution.
This document outlines the different types of vaccines.
Available in English, French, Spanisch, Arabic, Chinese and Russian
more
All vaccines work by exposing the body to molecules from the target pathogen to trigger an immune response – but the method of exposure varies. Here’s how DNA and RNA vaccines work.
INFO Zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019)–mit mRNA-Impfstoffen –
Erklärung für die Formulare
Verfügbar in Deutsch, Französisch, Italienisch und Englisch
Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfemp...fehlung ist es, Personen, die eine COVID-19-Impfung mit einem der nicht in der EU zugelassenen Ganzvirusimpfstoffen (CoronaVac, Covilo und Covaxin) oder dem Vektor-basierten Impfstoff Sputnik V erhalten haben, mit einem Impfschutz auszustatten, der vergleichbar mit dem einer Grundimmunisierung plus Auffrischimpfung mit einem mRNA-Impfstoff ist.
more
Cet article fait partie d’une série d’explications à propos de la mise au point et de la distribution des vaccins.
Available in English, French, Spanisch, Arabic, Chinese and Russian
Qu’est-ce qu’un vaccin? Comment fonctionnent les vaccins ARNm contre la COVID-19 et quelle est leur importance? Regardez cette vidéo pour tout savoir sur les vaccins ARNm sûrs et efficaces contre la COViD-19
Swissmedic explique le fonctionnement d’un vaccin à ARNm dans le cadre campagne d’information de l'OFSP sur la vaccination contre le Covid-19. Plus d'infos sur https://ofsp-coronavirus.ch/vaccination
Alors que nous nous préparons à la mise en place de la vaccination COVID-19, voici une explication du fonctionnement des vaccins.
À mesure que la vaccination anti-COVID-19 se met en place à travers le monde, beaucoup de gens demandent à quoi il faut s’attendre, en particulier si les vaccins sont sûrs. La réponse est oui, mais voici quelques informations qui vous seront peut-être utiles.
updated version: 04/10/2021
Information about vaccine administration
Esta orientação provisória foi desenvolvida com base na recomendação emitida pelo Grupo Consultivo Estratégico de Especialistas (SAGE) em imunização, em sua reunião extraordinária de 5 de janeiro de 2021, e atualizada durante sua reunião extraordinária de 27 de maio de 2021 (2), sendo no...vamente atualizada em 19 de novembro de 2021 e em 19 de janeiro de 2022. Foram coletadas as declarações de interesses de todos os colaboradores externos, sendo elas avaliadas quanto a quaisquer conflitos de interesse. Os resumos dos interesses relatados podem ser encontrados no site da reunião do SAGE e no site do Grupo de Trabalho do SAGE. A orientação se baseia em evidências resumidas no documento de referência sobre a vacina de mRNA BNT162b2 (Pfizer-BioNTech) contra COVID-19 (4), sendo novamente atualizado com base em novos dados provenientes de publicações científicas.
more
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).